Prescription drug use and subsequent morbidity and mortality
The project will provide information on how medicines are used in the general population.
About the project
-
Project period: 01.02.2010 - 31.01.2026 (Active)
- Coordinating Institution: Norwegian Institute of Public Health
-
Project Manager:
- Vidar Hjellvik, Norwegian Institute of Public Health
-
Project Participants:
- Vidar Hjellvik, Physical Health and Ageing, Norwegian Institute of Public Health
- Zoltan Thinsz, Karolinska Institutet
- Peter Vestergaard, Aalborg University
- Morten Andersen, Karolinska Institutet
- Matti Siivola, University of Helsinki
- Mark C.H. De Groot, Utrecht University
- Marjanka K. Schmidt, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
- Jari Haukka, University of Helsinki
- Anna But, University of Helsinki
- Per Minor Magnus, Centre for Fertility and Health, Norwegian Institute of Public Health
- Tone Bjørge, Department of Global Public Health and Primary Care, University of Bergen
- Sara Ghaderi, Department of Global Public Health and Primary Care, University of Bergen
- Anders Engeland, Physical Health and Ageing, Norwegian Institute of Public Health
- Lars Jøran Kjerpeseth, Physical Health and Ageing, Norwegian Institute of Public Health
- Marte Handal, Mental Disorders, Norwegian Institute of Public Health
- Svetlana Ondrasova Skurtveit, Mental Disorders, Norwegian Institute of Public Health
- Ingeborg Hartz, Avd Forskning, Innlandet Hospital Trust
- Eva Skovlund, Department of Public Health and Nursing, Norwegian University of Science and Technology
- Jon Marius Grasto Wickmann, Health Studies, Norwegian Institute of Public Health
- Øystein Karlstad, Physical Health and Ageing, Norwegian Institute of Public Health
- Randi Marie Selmer, Physical Health and Ageing, Norwegian Institute of Public Health
- Kari Furu, Physical Health and Ageing, Norwegian Institute of Public Health
- Inger Johanne Landsjøåsen Bakken, Centre for Fertility and Health, Norwegian Institute of Public Health
- Helena Niemi Eide, Infection Control and Preparedness, Norwegian Institute of Public Health
- Mariam Anjum, Vestre Viken Hospital Trust
- Inger Ariansen, Physical Health and Ageing, Norwegian Institute of Public Health
Summary
Clinical trials of drugs have restrictions that limit the knowledge of new drugs at the time of marketing: relatively few people in a limited period of time have been exposed to the drug. Signs of adverse reactions should therefore be evaluated after the drugs have been taken in normal use by the population using epidemiological studies in which systematic bias is attempted to be avoided. Knowledge of how drugs are used in the population is also important. The project will provide information on how medicines are used in the general population - and on effects and side effects - by linking the Norwegian Prescription Database with the Cause of Death Register, the Patient Register, the Cancer Registry, health surveys (three counties, 40-year surveys 1985-1999 and CONOR 1994-2003) and socioeconomic information from Statistics Norway. The following specific issues are included:
a) Use of the insulin analogue Lantus and cancer risk.
b) Medicine use and diagnoses for ADHD.
c) Use of psychiatric drugs among children and adolescents.
d) Medical prevention of stroke in atrial fibrillation.
e) Drug treatment before and after hospital admissions for asthma.
f) The connection between the use of sedative medicine, sleep medicine, cancer and mortality.
g) Prescription drug use among cancer survivors.
h) Prescription of drugs for and mortality of cardiovascular disease
i) Sleep problems, hypnosis and later ADHD.